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Abstract: The skin is the largest organ of the human body and is the first line of defense against
physical and biological damage. Thus, the skin is equipped to self-repair and regenerates after
trauma. Skin regeneration after damage comprises a tightly spatial-temporally regulated process of
wound healing that involves virtually all cell types in the skin. Wound healing features five partially
overlapping stages: homeostasis, inflammation, proliferation, re-epithelization, and finally resolution
or fibrosis. Dysreguled wound healing may resolve in dermal scarring. Adipose tissue is long known
for its suppressive influence on dermal scarring. Cultured adipose tissue-derived stromal cells (ASCs)
secrete a plethora of regenerative growth factors and immune mediators that influence processes
during wound healing e.g., angiogenesis, modulation of inflammation and extracellular matrix
remodeling. In clinical practice, ASCs are usually administered as part of fractionated adipose tissue
i.e., as part of enzymatically isolated SVF (cellular SVF), mechanically isolated SVF (tissue SVF), or as
lipograft. Enzymatic isolation of SVF obtained adipose tissue results in suspension of adipocyte-free
cells (cSVF) that lack intact intercellular adhesions or connections to extracellular matrix (ECM).
Mechanical isolation of SVF from adipose tissue destructs the parenchyma (adipocytes), which results
in a tissue SVF (tSVF) with intact connections between cells, as well as matrix. To date, due to
a lack of well-designed prospective randomized clinical trials, neither cSVF, tSVF, whole adipose
tissue, or cultured ASCs can be indicated as the preferred preparation procedure prior to therapeutic
administration. In this review, we present and discuss current literature regarding the different
administration options to apply ASCs (i.e., cultured ASCs, cSVF, tSVF, and lipografting) to augment
dermal wound healing, as well as the available indications for clinical efficacy.
Keywords: adipose derived stromal cells; lipografting; wound healing; stem cells; stromal vascular
fraction; skin
1. Introduction
The skin is a physical barrier and the largest self-repairing organ of the human body and serves
multiple physiological functions, such as protection against dehydration and thermal, chemical,
or physical stress [1,2]. Repair of physical skin damage requires effective wound healing, which is
a dynamic process that involves five overlapping stages: homeostasis, inflammation, proliferation,
re-epithelization, and finally fibrosis [3]. These stages of wound healing are regulated by platelets
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and immune cells, such as monocytes and neutrophils, which secrete chemokines and cytokines that
attract and instruct other locally present cell types in the skin [4–7]. The skin consists of multiple layers
starting from the outside with the epidermis (consist of stratum corneum, -lucidum (only present in
hairless skin), -granulosum, -spinosum, and -basale), dermis, and a subcutaneous layer (a layer of
adipose tissue containing adipocytes embedded in the stromal vascular fraction (SVF)). The epidermis
is organized into hair follicles containing the interfollicular epidermis as well as sebaceous glands.
The interfollicular epidermis is maintained by hair follicle stem cells and associated progenitor cells,
which are also responsible for hair regrowth [8,9]. After physical damage of the epidermis, hair
follicle stem cells migrate to the wound area to regenerate this damaged tissue [9]. Besides hair
follicle stem cells and associated progenitor cells, the epidermis consists mainly of keratinocytes in
various stages of differentiation, starting at the stratum basale as basal keratinocytes [3]. During
life, basal keratinocytes continuously migrate upwards to the stratum corneum. At the base of the
stratum corneum, keratinocytes undergo apoptosis, which adds to layers of the stratum corneum
and functions to establish and maintain the physical barrier of the skin compromising environmental
factors [3]. The dermis comprises vasculature and nerves, as well as specialized extracellular matrix.
In this, elastin and collagen are pivotal, which provide, respectively, elasticity and tear-resistance to
the dermis [10]. Finally, the subcutaneous layer comprises adipocytes and SVF. The SVF consist of
all non-parenchymal (adipocyte) cell types i.e., fibroblasts, immune cells, endothelial cells, pericytes,
and adipose tissue-derived stromal cells (ASCs) [11,12].
Cultured ASCs secrete a plethora of angiogenic, anti-fibrotic, and anti-apoptotic growth
factors [13–15]. The isolation and characterization of ASCs from lipoaspirates was first described
by Zuk et al. in 2001 [13]. The possibility to isolate ASCs resulted in an increased rate of publications
that described the behavior and regenerative effects of ASCs with regard to important processes
related to dermal wound healing, such as angiogenesis and fibroblast migration [16,17]. Thus far,
however, the use of ASCs as a cellular therapy for dermal wound healing has only obtained the
status of a clinical experimental treatment modality. Although there are several reports and studies
indicating a regenerative effect of the use of ASCs, sound scientific evidence is lacking: there are
no prospective randomized clinical trials that support the postulated influence of ASCs. Moreover,
the harvesting and processing procedures of ASCs are highly variable while randomized clinical
trials warrant uniform procedures. Firstly, a single-cell suspension of ASCs can only be efficiently
isolated enzymatically. The use of enzymes, such as collagenase, to disassemble intact adipose tissue
or lipoaspirates to prepare a cell suspension-based SVF (cSVF) is legally forbidden in many countries.
Secondly, intraoperative enzymatic isolation procedures are time-consuming and expensive [12].
In clinical perspective, the most relevant hurdle of enzymatic methods is the poor retention of cells
after administration of single-cell suspensions of ASCs. This is relevant in skin applications, in which
the ubiquitous lymphatics may rapidly drainage via lymphatics that are abundantly present in skin,
in particular, in wound beds [18]. Nowadays, it is proven that also ASCs can be found concentrated in
SVF that is mechanically isolated from adipose tissue while these procedures are significantly simpler
and faster than enzymatic procedures [12].
In this overview, we present current literature regarding the different options to administrate
ASCs (i.e., cultured ASCs, SVF, and lipografting) to augment dermal wound healing, as well as the
thus far available indications for clinical efficacy.
2. Adipose Derived Stromal Cells as Cellular Therapy for Dermal Wound Healing
In dermal wounds, the parenchymal tissue of the skin is damaged and needs to be remodeled
in order to regenerate tissue. Regeneration of damaged parenchymal tissue is postulated to be
under the control of autologous stromal cells i.e., ASCs. ASCs are mesenchymal stromal cells that
are present in SVF of adipose tissue, attached around vessels as pre-cursor cells (i.e., pericytes
and periadventitial cells) [19,20]. In vitro, ASCs have the ability to differentiate into multiple cell
lineages, like ectodermal, endodermal, as well as mesenchymal lineages [13,21,22]. Despite their
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lack of self-renewal, their differentiation capacity persuaded investigators to name ASCs adipose
derived stem cells [23–26]. In vitro, ASCs have a limited lifespan, with a limited proliferation potential,
and undergo senescence at higher passages. Nevertheless, this is probably irrelevant for therapeutic
use of ASCs for wound healing because irrespective of proliferation, ASCs are able to differentiate (be
constructive), secrete growth factors and cytokines (be instructive), and can remodel the extracellular
matrix (be reconstructive) [27].
To date, two clinical trials directed at safety of revascularization after critical limb ischemia,
have investigated the use of cultured ASCs for critical limb ischemia (Table 1) [28,29]. In both
studies, cultured ASCs were injected intramuscularly to treat patients with non-healing ischemic
ulcers. In twelve patients the response rate of ulcer healing was 66.7% of the patients after six
months [29]. Moreover, an overall decrease in pain and improved walking distance in claudication as
compared to the baseline was noted after six months. The long-term outcome is unknown unfortunately.
In the other trial, only seven patients were treated, of which four patients underwent amputation
within five months after injection of ASCs [28]. Three non-amputated patients reported a decrease
of pain six months postoperative. Besides the amputations, no serious complications were reported
in both studies (Table 1) [28,29]. The improved ulcer healing, at least partly, appears to relate to the
augmented angiogenesis by the administered ASCs. Although the results from these non-controlled,
small-scaled studies are promising for part of the treated patients, the therapeutic effect needs to be
corroborated in randomized, placebo-controlled large trials. This is essential, if alone to distinguish
responders from non-responders and to determine optimal dosing, time-to-treat, frequency of dosing,
as well as to identify parameters that dictate efficient and effective wound healing in adipose tissue or
its constituents.
Large proportion of patients did not respond after administration of cultured ASCs. This lack
of effect of ASCs might relate to disturbed migration and/or disposal of ASCs via the circulation
and lymph system within the first 24 h after injection [18]. Other factors that influence the
therapeutic impact of ASCs are donor characteristics (e.g., age or co-morbidity, such as diabetes
mellitus), as well as the induction of senescence of ASCs after enzymatic isolation and culture [30–32].
The two studies on the therapeutic benefit of ASCs on critical limb ischemia, however, showed
that age or co-morbidity did not influence the therapeutic impact of ASCs [28,29]. Senescence
occurred when cells are cultured more than ten passages [32]. Senescent cells do not proliferate
or differentiate while these are pro-inflammatory and exhibit increased production of reactive oxygen
species (ROS) [33,34]. This senescent status is referred to as the senescence-associated secretory
phenotype (SASP), which impacts surrounding tissue cells. ROS accumulation inhibits proliferation
and proangiogenic capacities of ASCs which impairs their wound healing support [35]. Hyperglycemia
that is associated with diabetes may cause ROS accumulation in ASCs. Although we have shown that
ASCs are refractory to chronic hyperglycemia, their sensitivity to acute hyperglycemia is high [36,37].
Lee et al. used ASCs in passage 3, while Bura et al. did not mention the used passage number [28,29].
Furthermore, ASCs undergo phenotypic changes, other than senescence, upon several passages of
culture. During culture the phenotype and function of ASCs emerges, e.g., secretion of a plethora of
cytokines and growth factors, matrix metalloproteinases and extracellular matrix [19,38,39]. In vitro,
ASCs are a typical culture artefact that differs from their in vivo peers, which is an ill-conceived fact.
Therefore, the direct translation of in vitro characteristics of ASCs to their physiological function in
adipose tissue or SVF falls short of adequate scientific evidence. Therefore, the use of ASCs in their
natural habitation with their original function i.e., SVF or lipografting might result in a different
clinical outcome in comparison to cultured ASCs. This, however, does not preclude the study of the
therapeutic characteristics and benefits of cultured ASC.
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Table 1. Clinical studies of cultured adipose tissue-derived stromal cells (ASCs) as treatment of wound healing.
Reference Study Type Study Population Intervention Follow Up Results Complications







ulcers. Age of ulcers






Ulcer healing was determined
by measuring the largest
diameter of the ulcer, pain was
assessed with a VAS score and
limb ischemia was assessed by
TcPO2 with laser Doppler and
ABI after 1, 3 and 6 months.
4 patients underwent
amputation within 5 months
after treatment. Pain was
decreased in 3 patients.
TcPO2 was increased after 6













necrosis (n = 12).
Intervention:




Pain was evaluated with a
Wong Baker-FACES rating
score, an ABI was measured,
walking distances was
measured with a treadmill and
temperature changes were
measured with a
thermography after 6 months.
Ulcer healing occurred in 66.7%
of the patients. Pain was




walking distance did not (n =
5). * Temperature increased
after injection. ** No changes
in ABI were noted.
1 mild fever, 1 flu like
symptoms, 2 pain,
1 headache.
ASC = adipose derived stromal cells, VAS = visual analogue scale, TcPO2 = transcutaneous oxygen pressure, AB = ankle-brachial index. * Results were significant when p < 0.05. ** Results
were significant when p < 0.01.
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3. Cellular or Tissue Stromal Vascular Fraction as Treatment for Dermal Wound Healing
The legal ban on enzyme use to isolate SVF or ASCs is based on hypothetical increased risk of
animal-derived products, while these multistep procedures are considered undesirable manipulations.
Therefore, new intraoperative isolation procedures without the use of enzymes and animal derived
products have been developed, the so-called mechanical isolation procedures [12]. Mechanical isolation
procedures yield essentially intact tissue that is devoid of adipocytes, hence our proposed term:
tissue stromal vascular fraction (tSVF). In tSVF, the intact extracellular matrix with all of its bound
regenerative trophic factors, maintains the integrity of the stromal cells too [12,40]. In contrast,
enzymatic isolation procedures yield a SVF that comprises a suspension of cells (cSVF) that obviously
lack intercellular connections and extracellular matrix (ECM). The ECM is an important reservoir of
regenerative growth factors while ECM molecules and their degradation products also contribute
to the regenerative power of the ECM [12,41,42]. The predicted therapeutic capacity of cSVF,
therefore, is lower than of tSVF, which remains to be assessed in side by side comparative studies.
However, future therapies might comprise hybrids in which ECM is used to deliver and retain
ASCs in the wounds after injection. In this way, the ECM instructs ASCs to differentiate and secrete
their trophic factors to induce angiogenesis, remodel the native extracellular matrix, and reduce
inflammation for a longer time as compared to a single cell injection of ASCs [15,43]. Finally, ECM
components regulate proliferation and migration of cells as well as angiogenesis. An adequate
juxtracrine communication between different cell types e.g., pericytes and endothelial cells augments
angiogenesis [39]. Angiogenesis might even be further stimulated by the vasculature in tSVF,
which would result in reduced ischemia and thus reduced apoptosis [44]. This improves graft take
and survival of the transplanted tSVF as well as augmented dermal wound healing.
To date, several clinical studies report the use of cSVF to increase dermal wound healing
(Table 2) [45–49]. As of yet, none of these studies used tSVF as control or as experimental treatment.
In total, seventy-three patients with ulcers were treated with cSVF, of which sixty-three showed
complete healing. One study mixed cSVF with fibrinogen and thrombin and compared this with only
fibrinogen and thrombin after applying to diabetic ulcers [47]. 62% of the patients showed complete
healing after treatment with fibrinogen and thrombin. 100% of the patients showed complete healing
of the diabetic ulcers after treatment with cSVF in combination with fibrinogen and thrombin [47].
All studies, except the aforementioned study, also showed a decrease in wound-associated pain after
injection of cSVF. In one prospectively controlled study, ten patients with peripheral arterial disease
and chronic non-healing ulcers were treated with cSVF [45]. As a control, ten patients received no
treatment. This study showed that six out of ten patients presented complete ulcer healing while four
patients did not respond to the treatment [45]. No complications were reported in any study (Table 2).
These studies show that cSVF seems to be partly effective in increasing wound healing rates after
injection. Complete ulcer healing in all patients only occurred when fibrinogen, an extracellular matrix
protein, and thrombin was added to cSVF, suggesting that the use of tSVF might be more effective
in closing dermal wounds as compared to cSVF. After activation with thrombin, fibrinogen forms a
dense fibrin network that entraps the cells in cSFV, which mimics a native stromal tissue structure.
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Table 2. Clinical studies of cellular stromal vascular fraction (SVF) as treatment of wound healing.
Reference Study Type Study Population Intervention Follow Up Results Complications









ulcers of the lower
limb (n = 10 vs.
n = 10).
Intervention: 3 × 105 of cellular
SVF per ml (5 mL) injected at the
edge of the ulcers.
Control: non-treated
Results were evaluated
after 4, 10, 20, 60 and
90 days.
6 of the 10 patients treated with SVF
cells showed a complete healing of the
ulcer and a decrease of pain. 4 patients
treated with SVF cells did not respond.
No comparison data between










ulcers. Age of the
ulcer was at least 5
months (n = 15).
Intervention: 0.5–1 mL of cellular
SVF injected at the base of
the fingers.
Time until the wounds
were closed was
measured. A VAS score
for pain, a nail fold video
capillary scope for
capillary density and
echo-Doppler for the RI
score were used after 1,
3 and 6 months.
The mean time for ulcers to heal was
4.23 weeks (range 2–7 weeks). No new
digital ulcers appeared during the
follow-up. VAS score for pain and RI
score were decreased after 6 months as
compared to preoperative. *** An
increase in capillary density was
observed after 6 months with respect
to the baseline. ***
No complications
reported.








for at least 6 weeks
(n = 26 vs. n = 26).
Intervention: 4 × 106–8 × 108 of






evaluated by a blinded
panel after 8 weeks.
Complete ulcer healing occurred in all
patients in the intervention group,
while complete ulcer healing occurred











ulcers (n = 6).
Intervention 1: at least 20 × 106
of cellular SVF (20 mL) along the
arteries. Intervention 2 (after
2 months): at least 20 × 106 of
cellular SVF (20 mL).
Ulcer healing, pain,
changes in walking
distance as well as ABI
were evaluated after
12 months.
5 patients showed clinical
improvement, improvement in
walking distance, relief of pain and
ABI improvement. 1 patient
underwent a major amputation. No












Age of ulcers was at
least 6 months
(n = 16).
Intervention: cellular SVF (2.54
mL) injected into the border and





Reduction in wound size




evaluated within 2 weeks
after treatment.
11 patients showed complete
epithelialization within 71–174 days
postoperative. Postoperative pain
decreased from a mean value of 3.3
(range 1–5, median 3) to a mean value
of 0.6 (range 0–3.5, median 0.5).
No complications
reported.
SVF = stromal vascular fraction, VAS = visual analogue scale, RI = arterial resistivity index (resistance to blood flow caused by a microvascular bad distal to the measurement
site), ABI = ankle-brachial index. * Results were significant when p < 0.05. *** Results were significant when p < 0.001.
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4. Lipografting as a Treatment for Dermal Wound Healing
Lipografting, the transplantation of lipoaspirates i.e., fragmented adipose tissue, is widely
investigated in several clinical studies as a treatment to promote dermal wound healing [50–57].
Three prospective studies used lipografting in combination with platelet rich plasma (PRP) or cSVF to
treat lower extremity ulcers in ninety patients [53–55]. Cervelli et al., used PRP as additive to improve
cellular growth and differentiation of cells present in the lipograft as well as recipient cells [55]. As a
control, collagen and hyaluronic acid was used to treat lower extremity ulcers and vascular disease.
After 9.7 weeks on average, the ulcers of sixteen out of twenty patients (80%) had re-epithelialized
in the experimental group, while ulcers in five out of ten patients (50%) had re-epithelialized in
the control group after 8.4 weeks on average [55]. Although these differences suggest a therapeutic
impact of lipografts, the numbers were too low to allow for statistical significance. In a later study,
these authors treated patients with ulcers (n = 30) with PRP-enriched lipografts and showed complete
ulcer healing in 57% of the patients after three months [53]. In another follow-up, the same authors
compared cSVF enriched lipografting with hyaluronic acid as well as PRP-enriched lipografting with
bare PRP to treat posttraumatic lower extremity ulcers in forty patients [54]. This study showed similar
re-epithelialization rates for the cSVF enriched lipografting and PRP enriched lipografting groups,
respectively 97.9% ± 1.5% and 97.8% ± 1.5% after 9.7 weeks. The control groups showed similar
re-epithelialization rates as well with 87.8% ± 4.4% for the hyaluronic acid and 89.1% ± 3.8% for the
PRP group, which were significantly lower than for the cSVF and PRP enriched lipografting groups
(p < 0.05) [54]. These studies by the Cervelli group indicate that lipografting enriched with cSVF or
PRP promotes dermal wound healing. However, the comparison of cSVF or PRP enriched lipografting
to only lipografting, is required to assess the influence and necessity of the addition of cSVF or PRP to
lipografts in ulcer treatments.
Four other studies described the use of non-supplemented lipografts to treat non-healing ulcers
(n = 36). Two of these studies were case reports while none of the four studies had a control
group (Table 3). Van Abeelen et al. treated one patient with recurrent leaks from stoma and skin
excoriations with lipografting and prevented the stoma from leaking [50]. Another case report by
Caviggioli et al. used lipografting as a treatment for a posttraumatic leg ulcer in one patient. After one
month, the posttraumatic ulcer was closed [52]. One study was a prospective study by Stasch et al.
and described that lipografting augmented the complete healing of twenty-two out of twenty-five
non-healing diabetic ulcers, while one patient needed an additional lipografting session to finally
close the diabetic ulcer as well [57]. Klinger et al. retrospectively analyzed eight patients with
posttraumatic scars in combination with chronic ulcers and showed complete re-epithelialization
after lipografting [56]. Yet, without the comparison of lipografting with a placebo group the effect of
lipografting on dermal wound healing remains unclear. In all seven studies, a few minor complications
occurred, and, therefore, lipografting to promote dermal wound healing appears a relatively safe
procedure (Table 3).
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Table 3. Clinical studies of lipografting as treatment of wound healing.
Reference Study Type Study Population Intervention Follow Up Results Complications
van Abeelen et al.
2014 Case report
Patient with recurrent
leaks from her stoma
and skin excoriation.
Intervention: multiple layer




after 12 months. No clinical recurrence occurred.
No complications
reported.







ulcers (n = 9, 15 ulcers).
Age of the ulcer was
2–8 months.
Intervention: lipografting at







after 3 months. Another
6 months to 2 years of
follow-up was used to
evaluated any
ulcer recurrence.
10 of the 15 ulcers healed
completely in 8 to 12 weeks. In 2
patients (3 ulcers) amputation was
needed. In 2 patients, the ulcer size
decreased with 50%. All patient,




Caviggioli et al. 2012 Case report Patient with aposttraumatic leg ulcer.






after 1 week, 2 weeks, 1, 3,
6 and 12 months.
Complete wound closure was
obtained after 1 month. Patient
satisfaction was excellent.
Not mentioned.








disease (n = 20).
Intervention: lipografting in
the bed around the margins of
the ulcers. Co-intervention:





after 2 and 5 weeks and 3,
6 and 12 months.
16 of the 20 ulcers re-epithelialized
after 9.7 weeks on average in the
intervention groups compared to
5 of 10 ulcers re-epithelialized in
the control group after 8.4 weeks
on average. 13 patients needed
1 treatment, 5 patients needed









Patients with ulcers or
substance loss of the
lower limb (n = 30).
Intervention: lipografting in
the wounds. Co-intervention:
PRP injection, hyaluronic acid.
Results were evaluated
every week until 1 month
postoperative, then
follow-up was done 3,
6 and 12 months
postoperative. Biopsies
were taken intra-operative
and 15 days postoperative.
Complete healing occurred in
57% of the patients after 3 months.
Postoperative biopsies showed an
increased cell proliferation as
compared to intra-operative
biopsies. No quantitative data
was shown.
2 infections.
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Table 3. Cont.
Reference Study Type Study Population Intervention Follow Up Results Complications









Intervention 1: SVF enriched
lipografting into the bed of the
ulcer and peri-lesional.
Intervention 2: PRP enriched
lipografting into the
perilesional area. Control 1:
hyaluronic acid into the bed of
the ulcer. Control 2: PRP gels
into the bed of the ulcer.
Results were evaluated up to
16 weeks postoperative.
Biopsies were taken from a
small sample size (numbers
not mentioned) preoperative
and 3, 7 and 16 weeks
postoperative.
After 9.7 weeks,
re-epithelialization of the wound
occurred for 97.9% ± 1.5% for
intervention 1, 87.8% ± 4.4% for
control 1 *, 97.8% ± 1.5% for
intervention 2 and 89.1% ± 3.8%
for control 2. * No biopsy
comparison data between the four
groups was presented.
2 hematoma,
1 infection, 1 edema,





Klinger et al. 2010 Retrospective,non-controlled
Patients with chronic
ulcers within the scar






of the scar and edge and
central region of the ulcer.
Results were evaluated after
2 weeks.
Complete re-epithelialization
occurred in all patients after 2
weeks. Patient satisfaction was











limb ulcers (n = 25).
Age of the ulcer was
>2 months.
Intervention: sublesional
lipografting into the bottom of
the ulcer and the wound edges.
Co-intervention: debridement,
VAC dressing, sterile silicone
wound dressing, Octenisept®
and Suprasorb H® plates.
Time until wounds closed
and time until wounds
closed by 50% was measured.
Photographic evaluation of
the healing process.
22 of the 25 ulcers healed
completely after 68 days on
average. Mean wound size
reduction of 50% was achieved 4
weeks postoperative. One patient
needed a repeated lipografting
session and complete wound




PRP = platelet-rich plasma, SVF = stromal vascular fraction, VAC = vacuum assisted closure. * Results were significant when p < 0.05.
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The clinical efficacy of lipografting is usually ascribed to ASCs in the stromal vascular fraction,
more than to the adipocytes that comprise most of the lipograft’s volume. However, the ischemia that
occurs in lipoaspirates upregulates regenerative factors, such as fibroblast growth factors and vascular
endothelial growth factor, in particular in adipocytes. These growth factors promote angiogenesis and
proliferation of skin cells while these suppress apoptosis, thus could contribute to the wound repair
effect of lipografts [14]. Alternatively, one could envisage lipografting as a method to deliver ASCs
to the damaged skin to kick-start regeneration. This does not preclude that other regenerative cells
in adipose tissue such as the precursors of ASCs contribute to the therapeutic benefit of lipografts.
Moreover, the administration of ASCs as present in cSVF or tSVF, might be more beneficial in the early
phase of healing of chronic wounds because only a small volume is required. In this phase, cells with
regenerative capacity rather than large volume cells i.e., adipocytes, are warranted. In this way, (small)
chronic wounds can be treated already in the early phase which also restricts the risk of infection.
5. Conclusions
The administration of ASCs is promising as new therapy for the treatment of non-healing dermal
wounds. There is a variety of formulations of ASCs that can be injected i.e., as cultured cells, cSVF,
tSVF, or lipografts to augment dermal wound healing. However, due to the lack of well-designed
randomized placebo-controlled clinical trials, none of these formulations can be designated as optimal
to treat dermal wounds.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
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